Targeting malignant glioma cells in vitro using platelet-derived growth factor AA-based conjugates
2009 (English)In: Journal of drug targeting, ISSN 1029-2330, 1-10 p.Article in journal (Refereed) Published
Glioblastoma multiforme (GBM) is an unusually aggressive brain tumor; it is also highly heterogeneous. Poor prognosis and a median survival of less than 1 year, using conventional treatment, calls for development of new treatment strategies. Overexpression and/or amplification of platelet-derived growth factor alpha receptors (PDGFalphaRs) in GBM might act as potential targets for a novel therapeutic approach. In this study, conjugates based on PDGFAA-ligand and dextran, of different sizes (10 and 40 kDa dextran), were prepared and investigated regarding targeting properties in vitro. Three human malignant glioma cell lines, U343MGa31L, U343MGaCl2:6, and U563MG, were used because of their previously reported differences in receptor expression and behavior. PDGFAA-based 10 kDa dextran iodine-125 radiolabeled conjugates showed the most favorable properties according to results achieved in accumulation, retention, and localization of cell-associated radioactivity. In comparison with dextran-(125)I-tyrosine delivered radioactivity, the PDGFAA-based dextran conjugates confirm the potential of receptor targeting.
Place, publisher, year, edition, pages
2009. 1-10 p.
Conjugate, dextran, glioblastoma multiforme, PDGFAA, PDGF receptors, targeting
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-18470DOI: 10.1080/10611860902718698PubMedID: 19255898OAI: oai:DiVA.org:liu-18470DiVA: diva2:219696